Cyxone AB
Cyxone AB (publ), a clinical stage biotech company, develops disease modifying therapies for autoimmune and autoinflammatory diseases. Its product pipeline comprises Rabeximod, which is in phase II clinical development for the treatment of rheumatoid arthritis; and T20K for the treatment of multiple sclerosis and is in phase I trial. The company was founded in 2015 and is headquartered in Malmö, … Read more
Cyxone AB (CYXO) - Total Assets
Latest total assets as of June 2024: Skr33.01 Million SEK
Based on the latest financial reports, Cyxone AB (CYXO) holds total assets worth Skr33.01 Million SEK as of June 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Cyxone AB - Total Assets Trend (2015–2023)
This chart illustrates how Cyxone AB’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Cyxone AB - Asset Composition Analysis
Current Asset Composition (December 2023)
Cyxone AB's total assets of Skr33.01 Million consist of 42.4% current assets and 57.6% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 40.2% |
| Accounts Receivable | Skr494.00K | 1.1% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr23.64 Million | 54.2% |
| Goodwill | Skr1.00K | 0.0% |
Asset Composition Trend (2015–2023)
This chart illustrates how Cyxone AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cyxone AB's current assets represent 42.4% of total assets in 2023, an increase from 7.3% in 2015.
- Cash Position: Cash and equivalents constituted 40.2% of total assets in 2023, up from 0.9% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 54.0% of total assets, a decrease from 92.0% in 2015.
- Asset Diversification: The largest asset category is intangible assets at 54.2% of total assets.
Cyxone AB Competitors by Total Assets
Key competitors of Cyxone AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Cyxone AB - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Cyxone AB generates 0.12x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Cyxone AB is currently not profitable relative to its asset base.
Cyxone AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.02 | 2.78 | 2.90 |
| Quick Ratio | 2.02 | 2.78 | 2.90 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr3.54 Million | Skr 10.39 Million | Skr 8.38 Million |
Cyxone AB - Advanced Valuation Insights
This section examines the relationship between Cyxone AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.23 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -16.9% |
| Total Assets | Skr43.66 Million |
| Market Capitalization | $316.24K USD |
Valuation Analysis
Below Book Valuation: The market values Cyxone AB's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Cyxone AB's assets decreased by 16.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Cyxone AB (2015–2023)
The table below shows the annual total assets of Cyxone AB from 2015 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | Skr43.66 Million | -16.89% |
| 2022-12-31 | Skr52.53 Million | +13.87% |
| 2021-12-31 | Skr46.13 Million | -36.07% |
| 2020-12-31 | Skr72.15 Million | -3.94% |
| 2019-12-31 | Skr75.12 Million | -0.73% |
| 2018-12-31 | Skr75.67 Million | +84.27% |
| 2017-12-31 | Skr41.06 Million | +74.28% |
| 2016-12-31 | Skr23.56 Million | +3480.85% |
| 2015-12-31 | Skr658.00K | -- |